Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
4(33%)
Results Posted
33%(1 trials)
Terminated
1(8%)

Phase Distribution

Ph phase_3
2
17%
Ph phase_4
1
8%
Ph not_applicable
1
8%
Ph phase_2
6
50%
Ph phase_1
2
17%

Phase Distribution

2

Early Stage

6

Mid Stage

3

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
2(16.7%)
Phase 2Efficacy & side effects
6(50.0%)
Phase 3Large-scale testing
2(16.7%)
Phase 4Post-market surveillance
1(8.3%)
N/ANon-phased studies
1(8.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

4

trials recruiting

Total Trials

12

all time

Status Distribution
Active(6)
Completed(3)
Terminated(1)
Other(2)

Detailed Status

Completed3
Not yet recruiting2
Active, not recruiting2
Recruiting2
unknown2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
4
Success Rate
75.0%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (16.7%)
Phase 26 (50.0%)
Phase 32 (16.7%)
Phase 41 (8.3%)
N/A1 (8.3%)

Trials by Status

not_yet_recruiting217%
terminated18%
active_not_recruiting217%
recruiting217%
completed325%
unknown217%

Recent Activity

4 active trials
Showing 5 of 12
active_not_recruitingphase_2

2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy

NCT03004287
recruitingphase_2

BCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple Myeloma

NCT06793449
not_yet_recruitingphase_2

CAR-T vs. Auto-SCT: Which Works Better for New Myeloma Patients?

NCT07070934
recruitingphase_2

Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma

NCT06140966
not_yet_recruitingnot_applicable

Allo-HSCT vs ASCT in Adult T-LBL

NCT06741813
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT03004287Phase 2

2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy

Active Not Recruiting
NCT06793449Phase 2

BCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple Myeloma

Recruiting
NCT07070934Phase 2

CAR-T vs. Auto-SCT: Which Works Better for New Myeloma Patients?

Not Yet Recruiting
NCT06140966Phase 2

Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma

Recruiting
NCT06741813Not Applicable

Allo-HSCT vs ASCT in Adult T-LBL

Not Yet Recruiting
NCT04934475Phase 3

MInimal Residual Disease Adapted Strategy

Active Not Recruiting
NCT02295722Phase 1

GEMHDM2014 : Gem-HDM HDT and ASCT for Relapsed/ Refractory Lymphoma

Terminated
NCT00695409Phase 2

Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma

Completed
NCT00689169Phase 2

Targeted Intensification With ZBEAM and Autologous Stem Cell Transplantation in Patients With High-grade B-Cell Lymphoma

Completed
NCT02655458Phase 1

Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma

Completed
NCT01868828Phase 4

A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma

Unknown
NCT00499018Phase 3

Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma

Unknown

All 12 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
12